Gorjan Hrustanovic ^Investor

Gorjan Hrustanovic is a Managing Director at Biotechnology Value Fund (BVF Partners L.P.) with a strong background in biotechnology and oncology. He holds a Ph.D. in Biomedical Sciences from UCSF and has served on the boards of several biotech companies, including Kymera Therapeutics and Rain Therapeutics. Hrustanovic's research on ALK-fusion lung cancer has been published in reputable journals, showcasing his expertise in the field. He is fluent in Bosnian, Croatian, English, French, and Serbian, and is a member of the Evexia Bio Fund and Sigma Chi Fraternity. His passion for personalized medicine and molecular biology drives his work in the industry.